AbCellera
AbCellera is a biotechnology company specializing in the development of antibody medicines for various diseases, including cancer and autoimmune disorders, and partners with major pharmaceutical companies like Lilly and Moderna.
Services
AbCellera develops potential first-in-class and best-in-class antibody medicines. Their focus is on diseases like cancer, metabolic and endocrine conditions, and autoimmune disorders. The company utilizes proprietary technologies to discover and develop antibody medicines, making significant contributions to medical science.
Products
AbCellera plans to submit Investigational New Drug (IND) applications for two preclinical programs, ABCL575 and ABCL635, by 2025. These programs represent AbCellera's commitment to developing innovative treatments across various high-need areas. The company also specializes in developing technologies that unlock high-value drug classes and targets, including T-cell engagers and transmembrane proteins.
Strategic Partnerships
AbCellera collaborates with several major industry partners, including Regeneron, Lilly, Moderna, Gilead, and Novartis. These partnerships enable the company to leverage combined expertise and resources in the pursuit of creating groundbreaking antibody medicines.
Future Plans
AbCellera is building a clinical manufacturing facility near its headquarters, anticipated to be operational in 2025. This facility will produce GMP drug substance and drug products. Additionally, AbCellera plans to integrate process development, manufacturing, and regulatory capabilities to advance programs from targets to early clinical development.
Proprietary Technologies
AbCellera employs proprietary technologies for antibody discovery and development. These technologies enable the company to explore high-value drug classes and targets, contributing to the creation of innovative antibody medicines. Their advanced approach aids in addressing complex medical conditions through cutting-edge scientific methods.